1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Benjamin T Diamond, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Iberdomide, Carfilzomib, Daratumumab - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 2 | Recruiting | Benjamin T Diamond, MD | 30 | 2024-02-20 | 2026-03-11 |
Multiple Myeloma (1)
Acetaminophen (1) · Dexamethasone (1) · Diphenhydramine (1) · carfilzomib (1) · daratumumab (1) · iberdomide (1) · montelukast (1)
United States (1)
Benjamin Diamond, MD (1) · Carl O Landgren, MD, PhD (1)